2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections

US7582618B2 · kind B2 · utility

Assignees

• Idenix Pharmaceuticals LLC · US
• University of Cagliari · IT
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• L'Universite Montpellier II · FR

Inventors

• Jean-Pierre Sommadossi · Cambridge, US
• Paolo LaColla · Cagliari, IT
• Gilles Gosselin · Montpellier, FR

Key dates

• Filing date: Sep 6, 2006
• Grant date: Sep 1, 2009
• Expiry date: Dec 3, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.